Pfizer ‘Very Bullish’ On China Despite Slowdown
This article was originally published in PharmAsia News
Executive Summary
Pfizer said it saw "solid momentum" in emerging markets as 2015 came to a close, helped by growth for Prevenar in particular, and that it remains "very bullish" on China despite lower growth in this market.